Heart failure & cardiomyopathies
Multinational cost-effectiveness analysis of empagliflozin for heart failure patients with ejection fraction >40
Authors' conclusion
Empagliflozin was found to be the first targeted treatment option that is clinically effective and cost-effective for patients with HF LVEF > 40%.
Study context
- Population
- Patients with HF LVEF > 40%; United Kingdom (UK), Spain and France healthcare systemsmodel based on EMPEROR-Preserved data
- Exposure
- Empagliflozin + standard of care (SoC) vs SoC alone
- Outcome
- ICER per QALY gained
- Follow-up
- Lifetime
Methodological detailslifetime Markov cohort state-transition model, multinational (UK, Spain, France), healthcare system perspective, Inputs mainly from EMPEROR-Preserved trial data, published literature and country-specific databases
- Lifetime Markov cohort state-transition model
- Multinational (UK, Spain, France)
- Healthcare system perspective
- Inputs mainly from EMPEROR-Preserved trial data, published literature and country-specific databases
Main finding
As reported in the abstract
ICER per quality-adjusted life year (QALY) gained, UK
£14 851
ICER per QALY gained, Spain
€11 706
ICER per QALY gained, France
€15 447
Observational data: associations, not effects.
Further findings
| Outcome | SoC |
|---|---|
| Total lifetime cost per patient | |
| UK | £10 092 |
| Spain | €15 765 |
| France | €14 958 |
- Total lifetime cost per patient — Cost increase with empagliflozin added, UK
- £1407
- Total lifetime cost per patient — Cost increase with empagliflozin added, Spain
- €1148
- Total lifetime cost per patient — Cost increase with empagliflozin added, France
- €1485
HF hospitalisation or CV death
- Significantly reduced with empagliflozin + SoC vs SoC; key driver offsetting drug acquisition costs
Scenario analysis using NYHA functional class
- Similar results
Probabilistic sensitivity analysis
- Probability of cost-effectiveness at willingness-to-pay (WTP) £/€20 000/QALY, all three countries
- more than 50%
Original publication
Multinational cost-effectiveness analysis of empagliflozin for heart failure patients with ejection fraction >40. ESC Heart Fail. Published 5 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →